Drugs / Froniglutide
Froniglutide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01478399 | Dec 2011 → Oct 2012 | type 2 diabetes mellitus | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01236404 | Nov 2010 → Nov 2011 | type 2 diabetes mellitus | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05833711 | Sep 2023 → Mar 2025 | dermatomyositis | Immunoforge Co. Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01658501 | Jul 2012 → Jul 2013 | type 2 diabetes mellitus | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01427257 Comparator | Feb → Sep 2012 | type 2 diabetes mellitus | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Froniglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05833711 ↗ |
| Known as | Glymera | “Phase 1 Open-Label Pharmacokinetic, Safety and Tolerability Study of a Single Subcutaneous Dose of Glymera (PB1023) Injection in Subjects With Normal Renal Function and...” NCT01478399 ↗ |
| Known as | PB1023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01236404 ↗ |
| Known as | PF1801 | “Froniglutide (PF1801) 50 mg will be administered subcutaneously once a week.” NCT05833711 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314983 ↗ |
| Route | Subcutaneous | “Subcutaneous injection PB1023” NCT01236404 ↗ |